Lupin Limited's US subsidiary, Lupin Pharmaceuticals, Inc has been able to receive the final authorization for the company's Abbreviated New Drug Application for its lamotrigine tablets, 25 mg, 100 mg, 150 mg and 200 mg strengths, from the US Food and Drug Administration.